RNF19A couples tumour-intrinsic adaptation with immune suppression in castration-resistant prostate cancer and reveals sinomenine as a candidate intervention
摘要
Castration-resistant prostate cancer (CRPC) is characterized by tumour-cell adaptation and an immunosuppressive microenvironment, yet the molecular regulators linking these processes remain incompletely defined. By integrating single-cell transcriptomic datasets from hormone-sensitive prostate cancer and CRPC, we identified the E3 ubiquitin ligase ring finger protein 19A (RNF19A) as a CRPC-associated regulator enriched in basal-like epithelial cells. RNF19A depletion impaired prostate-cancer cell growth and tumour formation, increased apoptosis, and suppressed metabolic programmes related to ATP production and oxidative phosphorylation. Unbiased immunoprecipitation–mass spectrometry identified p53 as an RNF19A-interacting protein, and subsequent analyses showed that RNF19A promoted p53 ubiquitination and proteasome-dependent degradation, thereby supporting tumour-cell survival. RNF19A depletion also induced NF-κB- and inflammation-associated transcriptional programmes, suggesting that RNF19A may influence the inflammatory and immune-regulatory state of the tumour microenvironment. Spatial transcriptomic analysis showed that RNF19A-high tumour-like niches were associated with suppressive myeloid and exhausted-CD8-like programmes. Consistent with this observation, RELA was also identified as an RNF19A-interacting protein, and RNF19A promoted RELA ubiquitination and degradation, thereby restraining RELA-dependent NF-κB signalling, chemokine production and antigen-presentation-related programmes. Finally, structure-guided natural-product screening identified sinomenine as a candidate RNF19A-binding compound. Sinomenine bound recombinant RNF19A, reduced RNF19A abundance, inhibited prostate-cancer cell and patient-derived organoid growth, and suppressed xenograft growth. Together, these findings show that RNF19A sustains CRPC progression by promoting p53 and RELA degradation, thereby enhancing tumour-cell survival while limiting inflammatory and antigen-presentation-associated signalling. RNF19A therefore represents a potential therapeutic target in CRPC.
参考文献
1 Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 74, 229-263, doi:10.3322/caac.21834 (2024).
2 de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine 364, 1995-2005, doi:10.1056/NEJMoa1014618 (2011).
3 Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine 367, 1187-1197, doi:10.1056/NEJMoa1207506 (2012).
4 Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228, doi:10.1016/j.cell.2015.05.001 (2015).
5 Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (New York, N.Y.) 355, 78-83, doi:10.1126/science.aah4199 (2017).
6 Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.) 355, 84-88, doi:10.1126/science.aah4307 (2017).
7 Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science (New York, N.Y.) 377, 1180-1191, doi:10.1126/science.abn0478 (2022).
8 He, M. X. et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nature medicine 27, 426-433, doi:10.1038/s41591-021-01244-6 (2021).
9 Kiviaho, A. et al. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nature communications 15, 9949, doi:10.1038/s41467-024-54364-1 (2024).
10 Antonarakis, E. S. et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38, 395-405, doi:10.1200/jco.19.01638 (2020).
11 Xu, P. et al. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Journal for immunotherapy of cancer 11, doi:10.1136/jitc-2022-006581 (2023).
12 An, J., Wang, C., Deng, Y., Yu, L. & Huang, H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell reports 6, 657-669, doi:10.1016/j.celrep.2014.01.013 (2014).
13 Atanasov, A. G., Zotchev, S. B., Dirsch, V. M. & Supuran, C. T. Natural products in drug discovery: advances and opportunities. Nature reviews. Drug discovery 20, 200-216, doi:10.1038/s41573-020-00114-z (2021).
14 Zhang, N. et al. CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer. Drug Resist Updat 67, 100912, doi:10.1016/j.drup.2022.100912 (2023).
15 Luo, L. et al. Molecular cloning and preliminary functional analysis of six RING-between-ring (RBR) genes in grass carp (Ctenopharyngodon idellus). Fish Shellfish Immunol 87, 62-72, doi:10.1016/j.fsi.2018.12.078 (2019).
16 Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 116, 11428-11436, doi:10.1073/pnas.1902651116 (2019).
17 Zhu, Q. et al. RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination. Nature communications 12, 6653, doi:10.1038/s41467-021-27048-3 (2021).
18 Cheng, Y. et al. Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth. Journal of cellular and molecular medicine 25, 7796-7808, doi:10.1111/jcmm.16674 (2021).
19 Blomme, A. et al. THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO molecular medicine 14, e14764, doi:10.15252/emmm.202114764 (2022).
20 Liu, S. et al. Acetyl-CoA carboxylase 1 depletion suppresses de novo fatty acid synthesis and mitochondrial β-oxidation in castration-resistant prostate cancer cells. The Journal of biological chemistry 299, 102720, doi:10.1016/j.jbc.2022.102720 (2023).
21 Matoba, S. et al. p53 regulates mitochondrial respiration. Science (New York, N.Y.) 312, 1650-1653, doi:10.1126/science.1126863 (2006).
22 Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120, doi:10.1016/j.cell.2006.05.036 (2006).
23 Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559, 363-369, doi:10.1038/s41586-018-0266-0 (2018).
24 Jayaprakash, P. et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. The Journal of clinical investigation 128, 5137-5149, doi:10.1172/jci96268 (2018).
25 Lyu, A. et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature 637, 1207-1217, doi:10.1038/s41586-024-08290-3 (2025).
26 Dangaj, D. et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer cell 35, 885-900.e810, doi:10.1016/j.ccell.2019.05.004 (2019).
27 Gettinger, S. et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer discovery 7, 1420-1435, doi:10.1158/2159-8290.Cd-17-0593 (2017).
28 Ueda, R. et al. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proceedings of the National A
指标
DOI：
Submission ID：
下载次数
附加文件
补充文件
已发布
如何引用
下载引用
利益冲突声明
作者声明无任何需要披露的利益冲突。
Copyright
本预印本的版权持有者为作者/资助方。
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.